期刊文献+

结直肠癌KRAS基因突变检测及临床意义

下载PDF
导出
摘要 目的探讨结直肠癌患者KRAS基因突变特点与临床特征之间的关系。方法采用突变荧光定量PCR检测80例经手术证实的结直肠癌患者石蜡包埋肿瘤组织中KRAS基因第12、13密码子突变。结果 80例结直肠癌患者中有26例(32.5%)患者存在KRAS基因突变;第12密码子突变19例,突变检出率为23.75%,共检出6种突变类型,其中以Gly12Asp突变率(15%)最高;第13密码子检出1种突变类型(Gly13Asp)7例,突变检出率为8.75%。经统计学分析,KRAS基因突变与患者的性别、年龄、肿瘤部位、肿瘤分期无明显相关性。结论结直肠癌中KRAS基因突变的发生率较高,其突变率与性别、年龄、肿瘤部位、肿瘤分期无相关性。
出处 《延安大学学报(医学科学版)》 2015年第2期45-46,共2页 Journal of Yan'an University:Medical Science Edition
基金 延安大学附属医院研究生创新基金(12YJ23)
  • 相关文献

参考文献8

二级参考文献56

  • 1王志永,刘彤华.结肠粘膜,腺瘤和腺癌组织中Ki—ras癌基因突变的检测[J].中华病理学杂志,1993,22(6):333-336. 被引量:6
  • 2干月波,蔡心涵,郑树.结直肠癌病人粪便及组织中Ki-ras基因突变的研究[J].浙江医科大学学报,1995,24(6):241-247. 被引量:16
  • 3Lievrè A,Barhet JB,Boige V,et al.KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.J Clin Oncol,2008,26:374-379.
  • 4Benvenuti S,Sartore-Bianchi A,Di Nicolantonio F,et al.Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic rolorectal canrers to anti epidermal growth factor receptor antibody therapies.Cancer Res.2007,67:2643-2648.
  • 5Freeman DJ,Juan T,Reiner M,et al.Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving Panitumumab alone.Clinical Colorectal Cancer,2008,7:184-190.
  • 6Santini D,Loupakis F,Vincenzi B,et al.High concordance of KRAS status between primary colorectal tumors and related metastatic sites:implications for clinical practice.Oncologist,2008,13:1270-1275.
  • 7Lièvre A,Bachet JB,Le Corre D,et al.KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.Cancer Res,2006,66:3992-3995.
  • 8De Roock W,Piessevaux H,De Schutter J,et al.KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab.Ann Oncol,2008,19:508-515.
  • 9Benvenuti S,Sartore-Bianchi A,Di Nicolantonio F,et al.Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies.Cancer Res,2007,67:2643-2648.
  • 10Di Fiore F,Blanchard F,Charbonnier F,et al.Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy.Br J Cancer,2007,96:1166-1169.

共引文献129

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部